Advocates Applaud Launch of MTN-017, World’s First Phase II Rectal Microbicide Study

[IRMA press release]

 

Trial Design Significantly Enhanced By Strong Community Input

October 2, 2013 – IRMA applauds the launch of the world’s first-ever Phase II rectal microbicide trial. The Microbicide Trial Network’s study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.

“Today feels like every holiday imaginable rolled into one,” said Jim Pickett, chair of International Rectal Microbicide Advocates (IRMA.) “The launch of the MTN-017 study is a milestone long in the making and marks a giant leap forward in the development of safe, effective, acceptable, and accessible products that could be used to prevent HIV during anal intercourse.”

IRMA is pleased to have participated in an intensive community input process with the Microbicide Trials Network that included in-person consultations with advocates and key stakeholders in Thailand, South Africa, Peru and the United States. “The dreams and desires of many men, women, and transgender individuals the world over can be heard loud and clear in the design of the MTN-017 trial. This deep collaboration between scientists and community members is key to the success of this trial and to the rectal microbicide field in general,” said Pickett.

When microbicides were first imagined, they were “vagina-centric.” While many embraced the notion of creating vaginal products women could control, the majority of the HIV/AIDS community— scientists and advocates alike— dismissed the possibility of developing rectal microbicides for use during anal intercourse as an HIV prevention method. It was not considered feasible and the pursuit was seen as hopeless, even laughable. At best, the rectal microbicide field would consist of testing vaginal microbicides for rectal safety, because these products would undoubtedly end up in the rectum despite their intended destination.

IRMA thanks the visionary scientists, advocates and funders like the U.S. National Institutes of Health who bucked prevailing “wisdom” and have remained steadfast in their commitment to developing new HIV prevention methods for use during anal intercourse.

“I feel like we are taking two giant leaps forward today. One in the fight against HIV, and the other in the fight against ignorance and small thinking,” said Pickett.

# # # #

International Rectal Microbicide Advocates (IRMA) is a global network, housed at AIDS Foundation of Chicago, comprised of more than 1,200 advocates, scientists, policy makers and funders focused on rectal microbicide research and advocacy and related issues such as access to safe, condom-compatible lubricants.

Learn more about the MTN-017 study here.

Watch this video “The Rectal Revolution is Here: An introduction to rectal microbicide clinical trials” in English, Spanish, or Thai.

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

-------------------

Meet Javier Lopez, A Friendly Rectal Microbicide Advocate

Check out Javier Lopez's mini-bio, the latest in IRMA's "Meet a Friendly Rectal Microbicide Advocate" series on the IRMA website here.  Javier is one of five new bios posted this week.

 

Javier Lopez

New York City, USA

Javier Lopez first learned about rectal microbicides when his partner worked for Project Gel in Puerto Rico. Javier was immediately impressed by the creativity of this approach to HIV prevention as promotion of condoms alone is often difficult in all populations.

Soon after, he attended a talk on rectal microbicides by IRMA's Jim Pickett at Gay Men's Health Crisis (GMHC) in New York City. Then he was hooked and snatched up a few "Rectal Pride" stickers that now fabulously adorn his Ipad cover.

Javier has long been an advocate for HIV testing and for years has been involved in the HIV prevention fight in Puerto Rico. During his undergraduate studies he took part in numerous educational sessions for HIV/STI prevention in gay men. Currently, Javier is working as an assistant research scientist at the HIV Center for Clinical and Behavioral Studies that seeks to improve intervention screening practices for acute HIV infection in primary care setting in New York City. Soon Javier will be taking his education further as he enters the Masters of Public Health program at Hunter College in New York City.

Javier is also proud to have been a part of the recently launched HIV testing campaign for the CDC called "Reasons/Razones" which targets Latino gay and bisexual men to consider their reasons for getting tested. More information about this exciting campaign is available here.

Javier is excited to be a rectal microbicide advocate because he believes that it is important for this research to continue and that youth of all backgrounds should get involved.

Thank you Javier!

 

------------------- *Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content. -------------------

Meet Coco Alinsug, A Friendly Rectal Microbicide Advocate

Check out this interesting mini-bio of  Coco Alinsug, the latest in IRMA's "Meet a Friendly Rectal Microbicide Advocate" series on the IRMA website here.  Coco is one of five new bios posted this week.

  
Coco Alinsung
Boston, Massachusettes, USA

A native of the Philippines and a resident of Lynn, Massachusetts with his partner, Coco Alinsug has made a lifelong commitment to devote his time and energy to social justice, HIV/AIDS prevention, and issues facing LGBT youth.

Coco started his career as an HIV Counselor and Tester at the Gay and Bi Men's Health Program in Beverly, MA and later was appointed as the Executive Director of the North Shore Alliance on GLBT Youth which is funded by the Massachusetts Department of Public Health to provide HIV/STI education to youth 14-24 years old - a position he has held for eight years.

Currently Coco works as the Clinical Trials Field Recruitment Manager at The Fenway Institute where he has been for nearly seven years. It was in this role that Coco first came into contact with rectal microbicide advocacy as he was tasked with recruitment for all clinical trials, including the rectal microbicide study called Project Gel.

In his role at Fenway, Coco oversees outreach and recruitment for research studies looking at everything from possible HIV vaccines to microbicides to the use of pre-exposure prophylaxis (PrEP) to prevent HIV transmission. Coco and his team travel around New England, educating people about HIV and STD transmission and safer sex practices while also recruiting potential study participants.

Coco is also Chair for Community Education and Recruitment group for both HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) and sits as a member of the protocol team for two studies, HVTN505 and HPTN069. Coco also is a consultant for various HIV and STD Outreach Programs both in the North Shore and Boston, and sometimes organizes and hosts shows in several clubs.

Coco would also like to encourage IRMA to keep up the good work and always stay fabulous.

Thank you for all your work Coco, and you stay fabulous too!


------------------- *Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content. -------------------

Soooooooo..... Are Lubes Safe?

via Positive Lite, by Marc-André LeBlanc

"This situation is unacceptable. We’re in 2013, for the love of all that is wet and wild! How can we not know the answer to such a fundamental question—are lubes safe?" 

 Here I am again, standing in front of a giant wall of lube options at a local store.

• Water-based, silicone-based, oil-based, hybrid.
• Bottles, tubs, tubes, vats, vials, sachets, packets, pouches, pillows, mix-it-at-home kits.
• Pumpable, flippable, squeezable, scoopable, squirtable, spritzable, speadable.
• Regular, warming, cooling, tingling, numbing.
• Thick, thin, goopy, watery, greasy, sticky, slippery, silky, slick.
• Long lists of unpronounceable chemicals, claims of being organic or all-natural.
• Scents. Flavours. Colours.
• Formulated to look like cum!
• And of course, wildly varying prices.

I’m glad I’m not meeting that guy for another three hours. 

So which lube should I get? Which ones are safe? Which ones should I avoid? 

Who knows!

No, seriously. Who knows? If I don’t, I can only assume nobody else does. After all, I coordinate the global Lube Safety Working Group for IRMA—International Rectal microbicide Advocates. 

This is the shocking reality: more than 30 years into the HIV pandemic, we still have no clear answers on whether sexual lubricants (lubes) increase, decrease, or have no impact on the risk of acquiring HIV and other STIs sexually transmitted infections (STIs). 

Many men, women and transgender individuals all across the globe use sexual lubricants for both vaginal and anal intercourse. We have long promoted the use of male or female condoms with condom-compatible water-based or silicone-based lubes to prevent HIV and other STIs. Lubricants help ensure that condoms don’t break, and that condoms stay on during sex. So, it’s pretty critical we understand if any of these condom-compatible lubes could actually be putting people in harm’s way. 

One thing is clear: we will not get an answer to the lube safety question without advocacy.

Read the rest.

-------------------

  *Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

  -------------------

Press Release: More than 500 Endorsers Demand Answers on Lubricant Safety

 

Global coalition of organizations and individuals calls for research agenda to determine safety of sexual lubricants

For Immediate Release

June 12, 2013 – Over 500 organizations and individuals from nearly 60 countries have endorsed a Global Call to Action on Lubricant Safety. They all demand answers on whether sexual lubricants are safe for vaginal and anal intercourse. As the Call to Action points out, there are more questions than answers about the safety of sexual lubricants, and there are concerns that some of the products available on store shelves and at community-based organizations worldwide may actually cause harm.

International Rectal Microbicide Advocates (IRMA) launched the call to action, which prominent organizations across the globe subsequently endorsed, including the International Planned Parenthood Federation (IPPF), the Global Network of People Living with HIV (GNP+), the Global Network of Sex Work Projects, the Johns Hopkins Center for Public Health and Human Rights in the U.S., the Microbicide Trials Network, the Gay Men’s Health Crisis, National Black Gay Men’s Advocacy Coalition, Chicago Women’s AIDS Project, Woodhull Sexual Freedom Alliance, the Desmond Tutu HIV Foundation, African Men for Sexual Health and Rights, Terrence Higgins Trust, the Canadian AIDS Society, Asia Pacific Coalition on Male Sexual Health, and numerous other organizations devoted to sexual health and HIV prevention.

Several lubricant manufacturers—such as Trigg Laboratories (makers of WET), Davryan Laboratories (PROBE), Gel Works Pty (Wet Stuff), The Yes Yes Company (Yes), and Abra Advanced Research International Pte (SuperSlyde)—also joined this overwhelming global demand for answers on lubricant safety.

“After more than thirty years of the HIV pandemic, we still have no clear answers on whether sexual lubricants increase, decrease, or have no impact on the risk of acquiring HIV and other STIs,” said Marc-André LeBlanc, coordinator of IRMA’s International Lubricant Safety Working Group. “This is unacceptable. We urgently need a Lubricant Safety Research Agenda that will provide answers on lubricant safety.”

“Many men, women and transgender individuals all across the globe use sexual lubricants for both vaginal and anal intercourse," said Jim Pickett, IRMA chair. “Public health has long promoted the use of condoms with condom-compatible water-based or silicone-based lubricants to prevent HIV and other STIs. Lubricants help ensure condoms don’t break, and that condoms stay on during sex. So, it’s pretty critical we understand if any of these condom-compatible lubricants could actually be putting people in harm’s way.”

There are hundreds of different sexual lubricants on the market; however, researchers have only tested a few for tissue damage and to preliminarily assess potential impact on HIV and STIs. Because of this and relatively inconclusive results, it is nearly impossible to recommend or argue against specific brands of water-based or silicone-based lubricants.

While releasing this list of endorsers, IRMA continues to promote the development of a lubricant safety research agenda in partnership with advocates, researchers, and manufacturers across the globe. IRMA is working closely with key partners, such as the U.S. Centers for Disease Control and Prevention (CDC), which is conducting lube safety research, and the United States President’s Emergency Plan for AIDS Relief (PEPFAR), which is developing a Lube Safety Research Agenda with its Scientific Advisory Board.

IRMA eagerly awaits the release of data from the CDC’s latest study and PEPFAR’s Lube Safety Research Agenda. The new data and a PEPFAR -endorsed research agenda will move the lube safety issue forward.

“As a lubricant manufacturer, we are committed to working with advocates, funders, researchers and regulators to develop the safest possible products,” stated Sarah Brooks, CEO of Yes Yes Company Ltd. “That is why we enthusiastically endorse the Global Call to Action on Lubricant Safety. We want to be active partners by lending our expertise as a lubricant manufacturer.”

# # # #

Founded in 1985 by community activists and physicians, the AIDS Foundation of Chicago (AFC) is a catalyst for local, national, and international action against HIV/AIDS.

International Rectal Microbicide Advocates (IRMA) is a global network, housed at AFC, comprised of more than 1,200 advocates, scientists, policy makers and funders focused on rectal microbicide research and advocacy and related issues such as the safety of sexual lubricants.

See the Global Call to Action on Lubricant Safety and the complete list of endorsers here.

Learn more about lubricant safety here.

 

-------------------

 

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

 

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro. *Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

  -------------------

TIME SENSITIVE: Have You (or Your Organization) Endorsed Our Global Call to Action on Lubricant Safety Yet?

Have you and/or your organization endorsed the Global Call to Action on Lubricant Safety yet? (lists or endorsers in formation below.)

We are going to be closing the call soon, so please make your move on lube safety NOW.

Click here to read the Call and to endorse.

We must KNOW whether water-based and silicone-based lubricants used during sex are safe or not, whether they cause harm, or not. Right now we don’t know – but we DO have some data that has raised some concerns. These concerns must be addressed through research, the questions we have must be answered.

Make your voice heard – endorse the Call.

ORGANIZATIONS who have endorsed the Call = 159 to date

1.  Abra Advanced Research International Pte Ltd, Singapore
2.  ACON, Australia
3.  Act for Change, Ghana
4.  Act Up/East Bay, USA
5.  ActionAIDS, USA
6.  Adam's Love, Thailand
7.  ADEFHO, Cameroon
8.  Adhikaar, India
9.  Affirmative Action, Cameroon
10. African Alliance for HIV Prevention, South Africa
11. African Men for Sexual Health and Rights (AMSHeR), South Africa
12. Afrique Arc En Ciel, Togo
13. AIDES, France
14. AIDS Community Research Initiative of America, USA
15. AIDS Foundation of Chicago, USA
16. AIDS Project Los Angeles, USA
17. AIDS Services for the Monadnock Region, USA
18. AIDS United, USA
19. AKPAKA Axel, Benin
20. ALPHA Pittsburgh, Inc., USAALPHA Pittsburgh, Inc.
21. ALTERNATIVE CÔTE D'IVOIRE, Cote D’Ivoire
22. Anova Health Institute, South Africa
23. Asia Pacific Coalition on Male Sexual Health, Thailand
24. Asia Pacific Network of Sex Workers, Thailand
25. Astitva - An Organisation for the Support and Development of Sexual Minorities, India
26. Australian Federation of AIDS Organisations, Australia
27. AVAC, USA
28. Blue Diamond Society, Nepal
29. Canadian AIDS Society, Canada
30. Canadian AIDS Treatment Information Exchange (CATIE), Canada
31. Canadian HIV/AIDS Legal Network, Canada
32. Caribbean Association of Midwest America, USA
33. Case/UH Microbicide Clinical Trials Community Advisory Committee, USA
34. Center for Applied Research on Men and Health (CARMAH), Vietnam
35. Centre for Human Rights and Rehabilitation (CHRR), Malawi
36. Centre for the Development of People, Malawi
37. Chengdu Tongle, China
38. Chicago Female Condom Campaign, USA
39. Chicago Women's AIDS Project, USA
40. Citizen News Service – CNS, India
41. Club des 7jours, Togo
42. C-NET+, Belize
43. Coalition Internationale Sida PLUS, France
44. COCQ-SIDA, Canada
45. COMMUNITY AND FAMILY AID FOUNDATION-GHANA, Ghana
46. Community Information Center, USA
47. CONCEPTO VIH-SIDA E ITS, Mexico
48. Davryan Laboratories, Inc (Probe lubricants), USA
49. Desmond Tutu HIV Foundation, South Africa
50. Diversity And Solidairty Trust, Sri Lanka
51. DUH Demonstration for Universal Healthcare, USA
52. Epicentro, Peru
53. Equal Opportunities, Tajikistan
54. Evolve, Cameroon
55. Family Planning Council, USA
56. Fenway Institute at Fenway Health, USA
57. Freedom and Roam Uganda, Uganda
58. Fundacion Manodiversa Bolivia, Bolivia
59. Gala Initiative Uganda, Uganda
60. GALAEI, USA
61. Gay City Health Project, USA
62. Gay Men’s Health Crisis, USA
63. Gay Men's Sexual Health Alliance, Canada
64. Gel Works Pty Ltd, Australia
65. Global Forum on MSM & HIV (MSMGF), USA
66. Global Network of People Living with HIV, North American (GNP+NA), USA
67. Global Network of Sex Work Projects, UK
68. Global Research and Advocacy Group (GRAG), Senegal
69. GlobalGayz.com, USA
70. GrenCHAP Inc., Grenada
71. GWLmuda, Indonesia
72. Health Digest Foundation, Ghana
73. HealthHIV, USA
74. Heroes Project, India
75. HIV Prevention Justice Alliance, USA
76. House of Joe, USA
77. Housing Works, Inc., USA
78. Humanity First Cameroon, Cameroon
79. Hyacinth AIDS Foundation, USA
80. India HIV/AIDS Alliance, India
81. Interagency Coalition on AIDS and Development, Canada
82. International Center for Advocacy on Right to Health, Nigeria
83. International Planned Parenthood Federation, UK
84. International Rectal Microbicide Advocates (IRMA), USA
85. International Youth Council-Nigeria, Nigeria
86. IRMA ALC - América Latina y el Caribe, Peru
87. IRMA Nigeria, Nigeria
88. ISHTAR-MSM, Kenya
89. Iskorak, Croatia
90. Jamaica AIDS Support for Life, Jamaica
91. Johns Hopkins Center for Public Health and Human Rights, USA
92. Joint Adherent Brothers and Sisters Against Aids, Uganda
93. Los Angeles County HIV Drug & Alcohol Task Force, USA
94. Louisiana Latino Health Coalition for HIV/AIDS Awareness, USA
95. MAACA, INC, USA
96. Maritime Life Precious Foundation, Ghana
97. Men Against AIDS Youth Group, Kenya
98. Men For Health and Gender Justice Organisation, Botswana
99. Microbicide Trials Network, USA
100.  Minnesota AIDS Project, USA
101.  MUSC/Lowcountry AIDS Services Consumer Advisory Board, USA
102.  NAM Publications (Aidsmap), UK
103.  National Black Gay Men's Advocacy Coalition, USA
104.  National Minority AIDS Council, USA
105.  Naz Male Health Alliance, Pakistan
106.  New HIV Vaccine and Microbicide Advocacy Society, Nigeria
107.  Okaloosa AIDS support & Informational Services, Inc. (OASIS), USA
108.  PEMA Kenya, Kenya
109.  Penitentiary Initiative, Ukraine
110.  People Like Us (PLUS) Kolkata, India
111.  PeterCares House, USA
112.  POCAAN (People of Color Against AIDS Network), USA
113.  Positive Mind & Body Support Group Network, USA
114.  Positive Women's Network USA, USA
115.  Presbyterian AIDS Network, USA
116.  Pride Equality, Sierra Leone
117.  Pro Health Initiative, Nigeria
118.  Professionals in Pride Kenya (PPK), Kenya
119.  Project Inform, USA
120.  PT Foundation, Malaysia
121.  Puerto Rico Community Network for Clinical Research on AIDS, Puerto Rico
122.  Queer Alliance Nigeria, Nigeria
123.  QUEEROCRACY, USA
124.  Rainbow Community Kampuceah, Cambodia
125.  Rainbow Sunrise Mapambazuko, DR Congo
126.  Rainbow-Ethiopia in Exile (REE), USA
127.  Real Opportunities Network, Ghana
128.  San Antonio AIDS Foundation, USA
129.  San Francisco AIDS Foundation, USA
130.  SEA-AIDS (Asia Pacific eForum on HIV), India
131.  SIBALT, Russia
132.  SID'ADO, Cameroon
133.  Society Against Sexual Orientation Discrimination (SASOD), Guyana
134.  SOMOSGAY, Paraguay
135.  START at Westminster, USA
136.  Stichting AidsCare, The Netherlands
137.  Tamba Pwani, Kenya
138.  Tanzania Sisi Kwa Sisi Foundation, Tanzania
139.  Terrence Higgins Trust, UK
140.  Test Positive Aware Network, USA
141.  The Center for Sexual Pleasure and Health, USA
142.  The Initiative for Equal Rights, Nigeria
143.  The Mpowerment Project, USA
144.  The Yes Yes Company Ltd, UK
145.  Total Health Empowerment and Development (THEDI), Nigeria
146.  Treatment Action Group, USA
147.  Trigg Laboratories, Inc., USA
148.  Uganda Health and Science Press Association, Uganda
149.  UNITED AND STRONG INC, Saint Lucia
150.  Vivir. Participacion, Incidencia y Transparencia, A.C., Mexico
151.  Vote For Health Campaign, India
152.  We For Civil Equality NGO, Armenia
153.  William Way LGBT Community Center, USA
154.  Women`s Health, HIV and AIDS Southern Africa, Zimbabwe
155.  Womenplus Against TB and HIV in Kenya, Kenya
156.  Women's Health and Equal Rights Initiative, Nigeria
157.  Woodhull Sexual Freedom Alliance, USA
158.  World AIDS Forum, Australia
159.  Youth Voices Count, Thailand

Endorse.

INDIVIDUALS who have endorsed the Call = 310 to date

1.  Adam Fairris, UK
2.  Ako Cyriaque Yapo, Senegal
3.  Alan Johnson, USA
4.  Alapini Max, Benin
5.  Alberto Abello, USA
6.  Alex Carballo-Dieguez, USA
7.  Alicia Gauvin, USA
8.  Allison Boyd, USA          
9.  Amoussou Damien, Togo
10.  Andrew Reynolds, USA
11.  Angel Luis Hernández, Puerto Rico
12.  Ann Jones, USA              
13.  Ann Joseph, USA
14.  Anna Forbes, USA         
15.  Anna Saeger, USA
16.  Anne Lehocky, USA      
17.  Antonio Gonzalez, USA
18.  Arick Buckles, United States
19.  Ben Bavinton, Australia
20.  Ben Clapham, USA
21.  Ben Wilcock, Australia
22.  Bertram Johnson, United States
23.  Beth Galaska Burzuk, USA          
24.  Bi Petex, Uganda
25.  Bisi Alimi, United Kingdom
26.  Blake Smith, UK
27.  Bobby Ramakant, India
28.  Brian Kanyemba, South Africa
29.  Brian M. Green, USA
30.  Brian White, South Africa
31.  Briana Morgan, United States
32.  Brooke Willis, USA         
33.  Butch McKay, USA                         
34.  Cameron Wolf, USA
35.  Caren Kirkland, USA      
36.  Carlos Vela, Peru            
37.  Carrie E .Foote, USA
38.  Cassandra Warren, USA              
39.  Cassie Bayside, Australia
40.  Celina Londono, USA
41.  Champion Phiri, South Africa
42.  Chanthorn Phorng, Cambodia
43.  Charlene Dezzutti, USA
44.  Charles, Uganda             
45.  Chheav Aphyra, Cambodia
46.  Chiranjivi Amgai, Nepal
47.  Chris Bartlett, USA
48.  Christian Rumu, United States
49.  Christopher B. Duerkes, USA
50.  Chull Sesugh Stanley, Nigeria
51.  Clare Collins, USA
52.  Clayton Ruley, USA
53.  Collins Seymah Smith, Ghana
54.  Cory Silverberg, Canada              
55.  Courtney McCrellias, USA
56.  Dahlia Ferlito, USA
57.  Dan Kilbane, USA
58.  Dana Loxley, Australia  
59.  Dana Nelson, USA
60.  Daniel MacDonald, USA
61.  Daramola Christianah, Nigeria
62.  Darrel Johnson, United States
63.  David Acosta, USA
64.  David G Ostrow, USA
65.  David Kuria, Kenya
66.  David Phillips, USA         
67.  Deb Tolenaar, USA
68.  Deirdre Grant, USA       
69.  Denis Efremov, Russia
70.  Derrick Mapp, USA
71.  Don Pults, USA
72.  Donald MacIver, USA
73.  Donn Colby, Vietnam   
74.  Doug Brown, UK
75.  Doug McColeman, Canada
76.  Douglas Masinde, Kenya
77.  Douglas Warzyn, USA   
78.  Douomong Yotta Serge, Cameroon
79.  Dr Stuart Koe, Singapore
80.  Dr. Michael W. Plankey, USA
81.  Dredge Kang, USA
82.  Drew  Nannini, United States
83.  Duncan Japhta Khothatso Moeketse, South Africa
84.  Durueke Florita, Nigeria
85.  Dustin Kight, USA
86.  Ed Wolf, USA
87.  Edie O'Connor, United States
88.  Edward Fuchs, USA
89.  Edward Iwanicki, USA
90.  Eniko Akom, USA
91.  Eric Arnold Fopossi, Cameroon
92.  Eric Evans, USA
93.  Eric M Glare, Australia  
94.  Erich Schneider Ormeño, Peru
95.  Erik Libey, USA
96.  Erik Streeter, USA
97.  Ernest MOSEKI, Botswana
98.  Essiomle Ethie, Togo
99.  Eva Westley, United States
100.  Fiona Hale, UK
101.  Gabriel Boichat, Spain
102.  Gail Broder, USA
103.  Garland Wood, USA      
104.  Garry Brough, UK
105.  Gary Paul Wright, USA
106.  Gbekou, Togo
107.  Gennady Roshchupkin, Russia
108.  George Kerr, USA          
109.  George Miller-Zauner, USA
110.  George Pappas, USA
111.  George Reginald Freeman, Sierra Leone
112.  George Victor O, Kenya
113.  Georges S., Togo
114.  Georges Sideris, France
115.  Gerard Nkundimana, Rwanda  
116.  Gina Brown, USA
117.  Glenn Kornblum, USA  
118.  Gregg Kimball, USA
119.  Hanna Hjord, USA          
120.  Hannah Graves, Canada
121.  Heidi Nass, USA
122.  Heidi Wesbrock, USA   
123.  Helen, USA
124.  Henrieese Roberts, USA
125.  Hugo Dann, Canada
126.  Ian Lemieux, US             
127.  Ivan Cruickshank, Jamaica          
128.  J. Jeff McConnell, USA 
129.  Jace Dyckman, USA
130.  Jack Cox, USA
131.  Jade Patten, USA
132.  James Carrington, United States
133.  James Komar, United States
134.  Jamie Roberts, USA
135.  Jamie Sims, USA
136.  Jason Jacobs, USA
137.  Jason King , USA             
138.  Jean-Michel Brevelle, USA
139.  Jeff Berry, USA
140.  Jeffrey Pope, USA         
141.  Jennifer A. Hawley, USA
142.  Jeremy Kwan, Malaysia
143.  Jerome Galea, USA       
144.  Jeton Ademaj, USA
145.  Jim Cosenza, USA
146.  Jim Eigo, USA
147.  Jim Merrell, USA            
148.  Jim Pickett, USA
149.  Joan Tallada, Spain
150.  John Andrews, USA
151.  John Hamiga, USA         
152.  John Kashiha, Tanzania
153.  John McAllister, Botswana
154.  John Peller, USA             
155.  Jorge Gutierrez, USA
156.  Jorge Yon, Peru
157.  Joseph Alfano, USA
158.  Joseph Walker, USA
159.  Joyce Hunter, USA
160.  Jules Eloundou Atamba, Cameroon
161.  Julian Sanjivan, USA      
162.  Julie Davids, United States
163.  Kadiri Audu, Nigeria
164.  Karen Creary, USA         
165.  Karon Stephen, France
166.  Kasha Jacqueline, Uganda
167.  Kate Alexander, USA
168.  Kate Morrow, USA
169.  Kay Marshall, USA
170.  Kees Rümke, The Netherlands
171.  Keith Gereffi, USA
172.  Kelly Curran, USA
173.  Kennedy Otieno Olango, Kenya              
174.  Kenny, USA
175.  Kent Klindera, United States
176.  Kevin DeLuca, USA
177.  Kevin McKenzie, USA
178.  Kieta D. Mutepfa, USA
179.  Krishna Stone, USA
180.  Kyon Saucier, USA
181.  Larry Baxter, Canada    
182.  Laurel Sprague, United States
183.  Laxmi Narayan Tripathi, India
184.  Leo Schenk, The Netherlands
185.  Lillibeth Gonzalez, USA
186.  Linda Watson, Canada
187.  Loren Jones, United States
188.  Luis Galarza, Ecuador    
189.  Mac-Darling Cobbinah, Ghana  
190.  Maheswar Satpathy, Australia 
191.  Marc-André LeBlanc, Canada    
192.  Marcelo Maia, USA       
193.  Margaret Onah, Nigeria
194.  Marie Camacho, USA   
195.  Marie Omorodion, USA
196.  Mark Hubbard, USA      
197.  Mark Ing, USA 
198.  Mark S. King, USA          
199.  Marlon Woodward, USA
200.  Martha Tholanah, Zimbabwe
201.  Mary Brewster, United States
202.  Mathew Rodriguez, USA
203.  Matt Bray, USA
204.  Matthew Franck, USA
205.  Matthew Rose, USA
206.  Matthew Vaughan, Thailand
207.  Melanie A Reese, USA
208.  Michael Louella , USA   
209.  Michael Luciano, USA
210.  Michael Moore, USA    
211.  Michael Trigg, USA
212.  Mike Kennedy, Australia            
213.  Mike Peters, USA
214.  Mombunza Azuba, DR CONGO
215.  Monique Newell, USA 
216.  Morenike Ukpong, Nigeria        
217.  Muriel Visser, France   
218.  Mykaila Ostrom, USA
219.  Mykal Welch, Belize
220.  N. Nash, USA
221.  Naigaga Lillian Mutengu, Uganda
222.  Nathan Solomon, USA 
223.  Nicholas Bates, Australia
224.  Nnamani Ikechukwu Sammy, Nigeria
225.  Olumide Makanjuola, Nigeria
226.  Omullo Paul, Kenya
227.  Orbit Clanton, USA
228.  Otis Richardson, USA
229.  Patricia Segura, Peru
230.  Patrick French, USA
231.  Paul Causey, Thailand
232.  Pedro Goicochea, USA
233.  Penny DeNoble, USA
234.  Pham Thi Hanh Van, Vietnam
235.  Phillis Washington, USA
236.  Pilot Mathambo, Botswana
237.  Prince N. Bahati, Kenya
238.  Ramon Nunez III, USA
239.  Rebecca Giguere, USA 
240.  Remigus Emodi, Nigeria
241.  Rev. Charles Straight, USA
242.  Ricardo Jimenez, USA
243.  Richard Coover, USA
244.  Rita Lisa Labbett, US     
245.  Rob Camp, Spain
246.  Robert Aponte, USA
247.  Robert Birch, Canada
248.  Roger Cunha, USA
249.  Roger Pebody, UK         
250.  Roger Prasad, Canada
251.  Roger Tatoud, UK          
252.  Roy Wadia, India            
253.  Rukia Ahmed, Kenya
254.  S. Wakefield, USA
255.  Santiago Palomino, Peru
256.  Sasha Gear, South Africa
257.  Scot More, USA
258.  Scott Robertson, Zambia             
259.  Sedar, Benin
260.  Sergio Farfan, USA
261.  Shawn Decker, United States
262.  Shayna Buhler, Canada
263.  Shivani Thaker, USA
264.  Shreena, India 
265.  Sibusiso, South Africa
266.  Simon Odiwuor, Kenya
267.  Siobhan Fee, UK
268.  Solomon, Kenya
269.  Srun Srorn, Cambodia
270.  Steave Nemande, Cameroon
271.  Stephen Karpiak PhD, United States
272.  Stephen McGill, Liberia
273.  Stephen Miller-Zauner, USA
274.  Steve Miralles, Peru     
275.  Steven S. Muchnick, PhD
276.  Stuart Koe, Singapore
277.  Sue Saltmarsh, USA      
278.  Suman Nepal, Nepal
279.  Suraj Madoori, USA
280.  Susan Forrest, USA       
281.  Susan Lloyd Yolen, USA
282.  Susie Hoffman, USA
283.  Sylvie Rouby, France  
284.  Tendai F Mbengeranwa Mhaka, Zimbabwe
285.  Terence Roethlein, United States
286.  Teresa Springer, USA
287.  TG Green, USA
288.  Thandi Maluka, South Africa
289.  Theresa Rubin, USA      
290.  Thomas Haig, Canada
291.  Tiedjou Joseph Achille, Cameroon
292.  Timothy Frasca, USA     
293.  Timothy Kee, United States
294.  Titcha Ho, USA
295.  Trenado, France
296.  Trevor Pearson, USA
297.  Troy, USA
298.  Tung Duy Bui, Thailand
299.  Udom Likhitwonnawut, Thailand
300.  Vanessa Smith, USA
301.  Victor Rollins, Bahamas
302.  Vikram, USA
303.  Wanda Brendle-Moss, USA
304.  Wanda Commander, USA
305.  Will Wilson, USA
306.  William Booth, Canada
307.  Wolf Graf, Australia
308.  Yolanda, USA   
309.  Zoe Duby, South Africa
310.  Zoran Dominkovic, Croatia

Endorse. 

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,200 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

-------------------

African Common Position Paper Highlights Importance of Condom-Compatible Lubes and Rectal Microbicide Research

Our friends at AIDS Accountability International (AAI), in conjunction with The African Union Commission (AUC), recognised the need for greater African civil society organisation representation in the International Conference on Population Development (ICPD) process. So, tt was decided to create the African Common Position (ACP) on ICPD to reflect and include the perspectives, recommendations and expertise of African stakeholders.

The full ACP is available here. To sign on and endorse the Civil Society African Common Position please click here.

IRMA is excited to report that the need for safe, accessible, condom compatible lubricants as well as support for rectal microbicide research in Africa have been highlighted in the just completed African Common Position Paper (ACP) on ICPD. Our Project ARM - Africa for Rectal Microbicides effort is having an impact!

The specific sections on lube and rectal microbicides are as follows:

4.4.10. Recognise the need for further research into the role of anal and vaginal sexual lubricants for use as a tool to prevent HIV, STI’s and unplanned pregnancies, as well as its safety for users and compatibility with various other ingredients and condom varieties. Commit to making access to quality and affordable lubricants a reality for all people, as well as commit to funding for training and support for condom compatible lubricant use;

4.4.11. Train all health care workers, as well as procurement and head office ministry staff on new and evolving SRHR commodities especially with regard to HIV treatment and prevention technologies, this includes but is not limited to understanding the current vaginal and rectal micro-biocide and pre exposure prophylaxis fields in general and their specific programming implications for women and girls.

IRMA encourages you, or your organisation, to endorse the ACP. Click here to endorse.

Special thanks to IRMA member Tian Johsnon, one of the architects of Project ARM. His extraordinary leadership helped to make this happen. Kudos Tian!
Download the full African Common Position Paper here.

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,200 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

-------------------

Now Playing - The Rectal Revolution is Here

--- Now Playing ---  

"The Rectal Revolution is Here: An introduction to rectal microbicide clinical trials" on YouTube.

The vid, developed by IRMA, Microbicide Trials Network, and Population Council, is available in English,  Spanish and Thai languages.

Watch to learn about the need for rectal microbicides, how clinical trials work, and the importance of volunteers in the effort to make safe, effective, acceptable and accessible new HIV prevention tools.

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,200 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

  *Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

-------------------

VOICE Lesson: It's Unfair to be Non-Adherent

This post by IRMA's Jim Pickett first appeared on the blog of the HIV Prevention Justice Alliance.


The VOICE results are extremely important to the field of new prevention technology research. I hope current/future/much-needed discussions about VOICE don’t get drowned out by the HYPE (yes, all caps HYPE) surrounding the “baby cure” story which has dominated coverage out of CROI so far.

If there is one VOICE lesson to focus on, it is adherence. Or in this case, the upsetting lack thereof. It is absolutely important to fully understand why so many of the women in the trial didn’t apply the gel, or take the pill. And it is critically important for scientists to develop things people actually WANT to use, and DESIRE. Perhaps a daily gel, or a daily pill, is simply not desirable for a lot of folks. Makes sense to me.

But here’s the rub. The field can’t move forward with product development when people don’t actually test-drive the product being investigated. Products can’t be improved without data from people who actually used the product. Sure, a daily gel or a daily pill may not be everyone’s idea of a good time… but the only way those ideas get translated from the clunky Model T Ford to a slick 2013 BMW is through a long, iterative process. Which requires trial participants to APPLY THE GEL and/or TAKE THE PILL.

I get that people join trials for all kinds of reasons, and that for many; it is their only access to healthcare. So, they may have no interest in actually participating in test driving anything, but are very excited about regular HIV and STD screening, counseling, access to condoms and lube, referrals to other services, etc. Can’t be mad at them for wanting those things. Right?

It’s a crime, really, or at the very least an outrage, that clinical trials end up being the only healthcare access point for too many folks. That needs to be addressed, on its own.

But…we simply can’t afford enrolling thousands of people into complicated and costly clinical trials to have them just forgo what they SIGNED UP to do. Let’s be brutally honest here, joining a trial to get health screenings and condoms is great for the individual – but it does NADA, NOTHING, NOOTCH for the community/communities fighting HIV who are desperate for new tools to prevent HIV.

Being in a clinical trial is a commitment to following the protocol as best as possible, and being honest when unable. Clinical trial participation necessitates a strong sense of altruism, a desire to help answer big questions for whole populations. I think it is unfair to everyone, especially highly impacted communities where HIV rates are soaring, and where the crisis is anything but over, for trial participants to sign informed consents and derive individual benefits from trials without fully engaging in the study protocols that would allow for potential population benefits.

There are not unlimited resources. In fact, they are shrinking (Hello Sequester!) We can’t continue to fund expensive, resource-intensive, multi-year trials in which most people only SAY they test drove the product.

Jim Pickett is the Chair of the International Rectal Microbicide Advocates (IRMA). This blogpost is part of our ongoing coverage of the 2013 Conference on Retroviruses & Opportunistic Infections (CROI). To read more perspective and analysis on the VOICE results at CROI, click here.

-------------------

  *Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

  -------------------

IRMA Statement on VOICE Results

[Click here for the VOICE press release - "Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study" - from the Microbcide Trials Network]


IRMA, like the rest of new prevention technology researchers and advocates, is disappointed to learn that daily oral Truvada was not found to be an effective HIV intervention among the African women at risk for HIV who participated in the VOICE trial.

We applaud the efforts of the 5,029 women from South Africa, Zimbabwe, and Uganda who volunteered to participate in the VOICE trial. We also commend the Microbicide Trials Network and the National Institutes of Health for successfully executing this extraordinarily ambitious, important trial, and for contributing critical new information to the field.

Today at CROI 2013 we learned that the majority of women in the daily oral Truvada arm of VOICE were not taking their drugs regularly if at all. Rather than a biological explanation, it appears daily oral Truvada was not effective at preventing HIV among the women in the VOICE trial because the drug was not used regularly.

The results of VOICE indicate low adherence to all the drugs/regimens tested in the trial. There was also low adherence in the daily oral tenofovir and daily tenofovir gel arms. Both these arms were closed due to futility in late 2011 after separate reviews by the independent Data Safety and Monitoring Board. VOICE’s daily oral Truvada arm remained open until August 2012.

One of the biggest challenges the field faces is that of adherence. Clinical trials cannot show that a drug works to prevent HIV if trial participants do not take the drug. More must be done to accurately assess adherence during clinical trials in “real time”, and more must be done to develop HIV prevention interventions that people actually want to use, and like to use. But, we won’t be able to refine the drugs, the drug dosing strategies, and/or the drug delivery vehicles to make them more acceptable if trial participants are not adherent along the way.

Science is an iterative process. We are in the “car phone” phase of new prevention technologies - some of the drugs and dosing strategies are perhaps a little clunky. We all want to get to the “i-Phone” phase where we have interventions that are highly acceptable, and desired, but we won’t get there without going through the clunky phase first.

As the field moves forward, issues of recruitment are as important as adherence. Identifying potential trial participants who are most likely to be adherent during the trial is absolutely critical – and very challenging, as the way to achieve this is admittedly not clear.

The MTN-017 trial, a Phase II safety and acceptability study testing a reduced glycerin formulation of tenofovir gel, is getting ready to launch in the coming months. The study will enroll 186 gay men and transgender women at sites in Thailand, South Africa, Peru, and the United States, including Puerto Rico. It will be absolutely essential that MTN-017 volunteers take the study drugs as directed. If adherence is low during this trial, adequate amounts of safety data will not be collected, making it likely that efforts to develop tenofovir gel as a rectal microbicide will be halted permanently. Have no doubt, this would be a huge setback for rectal microbicide research, development, and advocacy efforts in general.

IRMA is very supportive of MTN-017’s inclusion of “real time” monitoring to assess adherence throughout the trial. This will allow investigators to understand and address challenges regarding adherence while the trial is underway, and will help participants make appropriate adjustments in “real time” to improve adherence outcomes. MTN-017 sites should also pay extra special attention to recruitment activities and work to engage and enroll individuals who are most likely to fully participate in the trial, and follow the various regimens being tested as directed.

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

-------------------

IRIN PlusNews: Lack of lube hurts HIV prevention

via IRIN PlusNews

“Key populations - such as MSM and sex workers - who need the lubricant the most, often get their health-related services from local NGOs, which are not often included in [HIV/AIDS] policies or broader [health] programmes,” explained Bidia Deperthes, a senior HIV adviser with UNFPA’s Comprehensive Condom Programming division in New York.

KATHMANDU, 21 February 2013 (PlusNews) - Safer-sex messaging on condoms is universal but the generally poor availability of lubricants, and awareness of them, is hindering HIV prevention, health activists warn.

Some personal lubricant - or “lube”- has been shown to lower the risk of HIV transmission by decreasing the risk of condoms breaking.

Despite preliminary proof of lube’s efficacy, far less of the product is procured and distributed than condoms, leading people to use alternative, sometimes harmful, substances during intercourse such as butter or petroleum jelly; oil-based lubricants weaken latex, making the condom more likely to break.

Activists say, however, that a blind spot in research on lubricants as a part of HIV prevention programmes means not enough is known about their impact on HIV risk.

Read the rest.

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

  *Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

  -------------------

IRMA Issues Global Call to Action: We Demand Answers on Lubricant Safety

More than 30 years into the HIV pandemic, we don’t know whether sexual lubricants increase, decrease or have no impact on the risk of acquiring HIV and other STIs.

This is unacceptable. We demand answers on lubricant safety.

We demand a Lubricant Safety Research Agenda.
 

Please join us. Click here to endorse this global Call to Action on Lubricant Safety.


You may endorse the Call to Action as an organization or as an individual. As advocates, funders, researchers, lubricant manufacturers and regulators, we are committed to come together to develop and implement a Lubricant Safety Research Agenda. Men, women and transgender people from around the globe who engage in vaginal or anal intercourse deserve access to safe, condom-compatible sexual lubricants. Endorse the global Call to Action now.

More info

Recent studies have raised questions about the impact of sexual lubricants on the risk of acquiring HIV and other sexually transmitted infections (STIs).

It is outrageous that more than 30 years into the HIV pandemic, we don’t know whether sexual lubricants increase, decrease or have no impact on the risk of acquiring HIV and other STIs. In fact, it is only recently that most advocates, HIV prevention workers, researchers and regulators have even realised that we don’t yet know the answers to these fundamental questions.

Today, there are only a few disparate studies related to lube safety underway. These studies do not form part of an overarching plan to answer questions about lubricant safety because there isn’t one.

This is unacceptable. We demand answers on lubricant safety.

We demand a Lubricant Safety Research Agenda and insist upon its quick implementation. We must know whether or not various types of sexual lubricants are safe for vaginal and rectal use. We must understand fully what impact they have on the risk of acquiring HIV and STIs.

•As advocates, funders, researchers, lubricant manufacturers and regulators, we are committed to come together to develop and implement a Lubricant Safety Research Agenda.

•As advocates, we support more research, funding, and collaboration to determine whether lubricants are safe.

•As funders, we will support the research and collaborative work required to determine whether lubricants are safe. Funding for lubricant safety research will not come out of budgets for microbicide research or other new prevention technologies.

•As researchers, we will conduct the appropriate studies required to determine whether lubricants are safe.

•As lubricant manufacturers, we will list the ingredients used to manufacture lubricants and work with researchers and regulators to ensure that our products are safe.

•As regulators, we will provide guidance into the research data required to ensure that lubricants available on the market are safe.

Endorse the Call to Action on Lubricant Safety

Men, women and transgender people from around the globe who engage in vaginal or anal intercourse deserve access to safe, condom-compatible sexual lubricants.

Please endorse this global Call to Action on Lubricant Safety. You may endorse the Call to Action as an individual or as an organization.

--------------------------------

Click here for more information about the safety of sexual lubricants. You will find links to factsheets, backgrounders, reports, articles and webinar recordings.

IRMA (International Rectal Microbicide Advocates) is a network of over 1,200 advocates, policymakers and leading scientists from six continents working together to advance a robust rectal microbicide research and development agenda, with the goal of creating safe, effective, acceptable and accessible rectal microbicides for the women, men, and transgender individuals around the world who engage in anal intercourse. Our priorities including pushing for safe, condom-compatible sexual lubricants, and concerted advocacy for adequate access to these important products for people all over the world.

 

Cell Damage Caused by Application of Certain Personal Lubricants Does Not Increase Risk of HIV Infection in Tissues Exposed to HIV in a Laboratory, According to a New Study

Below is an adapted version of the official MTN press release that went out moments ago on this study and associated PLoS One paper ("Is Wetter Better? An Evaluation of Over-the-Counter Personal Lubricants for Safety and Anti-HIV-1 Activity"). The IRMA modifications to the release - which do not alter any facts - underscore and emphasize that the study involved exposing human tissues to HIV in a laboratory setting. The study was not a clinical trial. It did not test lubricants in humans - an important fact to properly understand the context of the results.  

While IRMA believes this study is very interesting and adds significantly to our understanding of lubricant safety, the study DOES NOT answer the critical question of what actually happens in humans. Testing lubes on vaginal and rectal tissues in lab settings is important work, but the findings from these studies are unable answer the BIG question out there - which lubes are safer than others when applied rectally or vaginally in HUMAN BEINGS?

IRMA has long prioritized the issue of lube safety, and once again we ask: Where is the commitment to fund and conduct lube safety studies that answer the critical question of REAL LIFE CONSEQUENCES?  

When will we get the answers we need regarding the effects of lube in HUMANS when lube is used IN REAL LIFE? 

--Aidsmap's excellent article on this study: Some sexual lubricants damage cells – but may not increase HIV risk. 

--Click here for more IRMA info on lubricant safety, with resources including a fact sheet and an extensive QA document. 

Cell Damage Caused by Application of Certain Personal Lubricants Does Not Increase Risk of HIV Infection in Tissues Exposed to HIV in a Laboratory, According to a New Study

 PITTSBURGH, Nov. 7, 2012 – The use of certain water-based, over-the-counter personal lubricants can dry out and irritate vaginal and rectal tissue, but does not appear to increase susceptibility to HIV in vaginal tissues exposed to HIV in a laboratory setting, according to a study published today in PLoS ONE. Even so, say study authors affiliated with the National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), more research is needed to fully understand the safety of personal lubricants and their effect on epithelial tissue, the layer of mucosal cells that acts as the body’s first line of defense against sexually transmitted HIV.

“We tested several kinds of personal lubricants [IN THE LABORATORY] and those that did the most damage to cell tissue were hyperosmolar,” said lead study author Charlene S. Dezzutti, Ph.D., associate professor of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine and principal investigator of the MTN Network Laboratory.

“While we know there is cellular toxicity associated with hyperosmolar lubes, the damage did not appear to make cells more vulnerable to HIV infection,” Dr. Dezzutti explained.

Hyperosmolar lubricants contain more salts, carbohydrates and proteins than are typically found inside cells of the vagina or rectum. This imbalance causes epithelial cells to lose water and, as a result, dry out. They are different from iso-osmolar lubricants, which contain the same amount of salts and other ingredients as do the cells.

Study investigators tested 14 brand-name over-the-counter and mail-order water-, lipid- and silicon-based lubricants. Lubricants selected were identified as those most commonly used during anal sex in a survey, conducted by IRMA, of more than 6,300 respondents. Results indicated that hyperosmolar water-based lubricants caused the most damage to the epithelium taken from the vagina and rectum compared to iso-osmolar water- and silicon-based lubricants.

When the researchers applied the lubricants to tissue taken from the vagina and then exposed the tissue to HIV, they found that the lubricants did not increase the tissue's susceptibility to HIV infection.

Other studies are seeking to address HIV susceptibility with rectal tissue.

Of the lubricants tested in the lab, Good Clean Love and PRÉ, both water-based iso-osmolar lubricants, were shown to be least harmful to epithelial tissue, along with two silicon-based lubricants, Female Condom 2 and Wet Platinum. Lubricants that were most toxic to the epithelial tissue (Gynol II, KY Jelly and Replens) also tended to damage “good” bacteria called lactobacillus, which is needed to maintain a healthy genital tract.

“Much more work needs to be done to explore the safety of lubes,” said Dr. Dezzutti. “This was an early study and the jury is still out as to whether hyperosmolar lubes cause damage to the epithelium that in conjunction with other processes, like inflammation, could increase susceptibility to HIV.”

“The most important point for people to take away from this study is that condoms are still the best way to protect against HIV and that lubes should always be used with compatible condoms.”

In addition to Dr. Dezzutti, authors include Elizabeth R. Brown, Ph.D., Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle; Bernard Moncla, Ph.D., Julie Russo, Marilyn Cost, Lin Wang, Kevin Uranker, Ratiya Kunjara Na Ayudhya, Kara Pryke, Lisa C. Rohan, Ph.D., with the MTN and the University of Pittsburgh; and Jim Pickett and Marc-André LeBlanc, with International Rectal Microbicide Advocates, Chicago.

The study was funded by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, all components of the NIH. 


Click here for more info on lubricant safety from IRMA, with resources including a fact sheet and an extensive QA document.

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

  -------------------

Meet Annette Larkin, A Friendly Rectal Microbicide Advocate

Check out this interesting mini-bio of  Annette Larkin, the latest in IRMA's "Meet a Friendly Rectal Microbicide Advocate" series on the IRMA website here.  Annette is one of five new bios posted last week.



Annette Larkin
Alexandria, Virginia, USA

"It's possible that microcides will really find a home in the rectum, so to speak."

Annette is an IRMA advocate, a communications consultant and a guest lecturer at Georgetown University's grad school for communications. She is also the assistant editor of North Wind Magazine. Annette has additionally been working with CAMI - Coalition Advancing Multipurpose Innovations.

Besides being a fabulous IRMA advocate, Annette enjoys travelling, watching HBO's 'Girls', and hanging out with her gorgeous daughter Bella and boyfriend.

Annette first started engaging with IRMA because she found the group very dynamic and engaging and wanted to join in. Additionaly, she has workd with CONRAD, the developer of tenofovir gel for vaginal as well as rectal use.

Annette believes that rectal microbicides are important as a new HIV prevention technology because there seems to be an increase in the amount of people having anal sex, and lube is needed to maximize pleasure anyway. Her advice to IRMA is to keep believing in rectal microbicides!

Thank you, Annette, for all that you do!

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

  -------------------

Meet Jim Higginbotham, A Friendly Rectal Microbicide Advocate

Check out this interesting mini-bio of  Jim Higginbotham, the latest in IRMA's "Meet a Friendly Rectal Microbicide Advocate" series on the IRMA website here.  Jim is one of five new bios posted last week.




Jim Higginbotham
Birmingham, Alabama, USA

"I must continue to inspire others, especially the younger generation to carry the torch until the end of HIV."

Jim is the Community Educator for HIV Vaccines at the University of Alabama Birmingham - a site for a number of biomedical HIV prevention trials. He loves helping his community in the fight against HIV through education and counseling. During his spare time, Jim enjoys spending time at his family farm, kayaking, hiking, and camping.

Jim initially became involved with IRMA while attending Microbicide Trials Network meetings and conferences. He recruited men to participate in MTN 007, which was a rectal microbicide study that included the University of Alabama clinical research site. Jim believes that a combination of prevention strategies must be utilized to reduce the number of infections that continue to occur in the United States and around the world and asserts that "a rectal microbicide, marketed as a lubricant, could help achieve that goal because it would, in my opinion, be embraced by individuals who engage in anal sex as an easy way to protect themselves."

Jim advises IRMA to keep up the good work in helping to educate the community on the need for rectal microbicides. Currently, Jim is recruiting and screening individuals for the HVTN 505, a vaccine study.

Jim has lost many friends to HIV/AIDS... a loss which continues to inspire his involvement in the fight for prevention and treatments. Jim is the sole survivor of his original peer group of friends from his early twenties.

"If I had to point to one individual as an inspiration, I would have to say that person is Butch McKay, a great friend and tireless advocate for the community in the fight against HIV. Butch has inspired me more than anyone to do the work that I do."

Thank you, Jim, for all that you do!

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

  -------------------

Meet Clare, A Friendly Rectal Microbicide Advocate

Check out this interesting mini-bio of  Clare Collins, the latest in IRMA's "Meet a Friendly Rectal Microbicide Advocate" series on the IRMA website here.  Clare  is one of five new bios posted October 30, 2012.



Clare Collins
Pittsburgh, Pennsylvania, USA

"I think rectal microbicides just make sense. The idea of a product that people might actually WANT to use to protect themselves against HIV is a no-brainer."

Clare is an Associate Director of Communications and External Relations at the Microbicide Trials Network (MTN), where she works to promote MTN's rectal microbicide agenda. She also works to strategize the best ways to communicate with others concerning complex health information around biomedical HIV prevention. After starting at the MTN in 2010, she got involved with IRMA through reaching out to IRMA chair Jim Pickett and believes rectal microbicides are a very important part of the HIV prevention research agenda.

Currently Clare is busy planning for the launch of the first-ever rectal microbicide Phase II trial (MTN 017), testing a reduced-glycerin version of tenofovir gel for safety and acceptability among gay men, other men who have sex with men, and transgender women at domestic and international sites. The first site is expected to open enrollment sometime in December 2012. Clare is also part of a team (including IRMA and Population Council) that developed a new educational video, "The Rectal Revolution is Here: An Introduction to Rectal Microbicide Clinical Trials," which will be launched at the same time MTN 017 starts. The video is 13 minutes long and will be available on YouTube. It features animation and live action, and has English, Spanish, and Thai versions.

Clare has been greatly influenced by her mother, who taught her valuable lessons about compassion and concern for others through her battle with cancer, including the necessity of universal access to health care. She is very excited about the future and looks forward to seeing the evolving research in this area.

Thank you, Clare, for all that you do!

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

  *Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

-------------------

Meet Jeton, A Friendly Rectal Microbicide Advocate

Check out this interesting mini-bio of  Jeton Ademaj, the latest in IRMA's "Meet a Friendly Rectal Microbicide Advocate" series on the IRMA website here.  Jeton is one of five new bios posted October 30, 2012.



Jeton Ademaj
New York City, USA

"Don't be afraid to own your sexuality, and don't be afraid to defend human nature from those who presume to redefine it."

For several years, Jeton remained unaware of IRMA's work, but became involved as communities began to really take notice of PrEP in 2011. IRMA's active listserv has provided a platform for a great deal of discussion and debate on the topic.

Jeton believes rectal microbicides are important because, in general, he believes that men dislike condoms and research has yet to create more pleasurable and desirable condoms to enhance usage. Through rectal (and vaginal) microbicides, receptive individuals can become empowered in preventing HIV/STI transmission, without having to get permission from the active partner to use protection.

Jeton advises IRMA to not be afraid to defend human nature, despite one's sexuality. He encourages IRMA to always publicize the work to further encourage researchers to become involved in IRMA's mission.

Currently, Jeton contributes as a voice of reason in certain POZ settings, and advocates for human rights through progressive politics.

Jeton loves spending time with his husband, reads various scientific and technological developments, and listens to live music. His biggest influences come from his family, his best friend, and his husband.

Thank you, Jeton, for all that you do!

-------------------

  *Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

-------------------

AIDSTAR-One - Ready, Set, Rectal Microbicides: An Update on Rectal Microbicide Research and Advocacy

via AIDSTAR-One, by Jim Pickett (IRMA chair)

[This article was written for AIDSTAR-One's "Spotlight on Prevention" series.]

Until recently, microbicide research has focused on vaginal microbicides. Recent initiatives and ongoing studies highlight the need for safe and effective rectal microbicides as part of an essential HIV prevention toolkit.

Around the turn of the millennium, the microbicide field was almost solely focused on the research and development of vaginal microbicides, and community engagement and advocacy aligned with this priority. If scientists and advocates considered rectal microbicides (RMs) at all, it was strictly in the context of the need to test vaginal products for rectal safety, with the understanding that when a vaginal microbicide made it to market, it would likely be used in the rectum as well, or would migrate there during vaginal intercourse.

The realities of the HIV epidemic, though, point to anal intercourse (AI) as a practice that both men and women engage in, and as a significant factor in the spread of HIV and other sexually transmitted infections (STIs). The work of a growing number of scientists and advocates has brought us to the early days of a new consciousness some are calling “the rectal revolution,” where researchers are investigating the role of RMs and related products as essential elements of HIV prevention. This summary describes where we are in the rectal revolution, and where we need to go.

Read the rest.

Download the PDF.

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

-------------------